2009年10月12日 · We have recently synthesized a novel proteasome inhibitor (BU-32) and tested its growth inhibitory effects in different breast cancer cells including MCF-7, MDA-MB-231, and SKBR3 by in vitro cytotoxicity and proteasomal inhibition assays. The apoptotic potential of BU32 was tested using flow cytometry and analyzing cell cycle regulatory proteins.

In this study, we evaluate the efficacy of the novel proteasome inhibitor BU-32 (NSC D750499-S) using in vitro and in vivo breast cancer models.

方法我们最近合成了一种新型蛋白酶体抑制剂 (bu-32)，并通过体外细胞毒性和蛋白酶体抑制试验测试了其对不同乳腺癌细胞（包括 mcf-7、mda-mb-231 和 skbr3）的生长抑制作用。使用流式细胞术和分析细胞周期调节蛋白来测试 bu32 的凋亡潜力。

2008年5月1日 · The efficacy of the novel proteasome inhibitor BU-32 (NSC D750499-S) is evaluated using in vitro and in vivo breast cancer models and the results suggest its potential benefit in breast cancer treatment. Expand. The results suggest that BU-32 might be a potential chemotherapeutic agent with promising antitumor activity for the treatment of MM.

2008年5月1日 · We have synthesized a novel proteasome inhibitor (BU-32) which shows promising inhibitory activity against MDA-MB-231 cells in the human breast cancer xenograft nude mouse model. BU-32 exhibits strong cytotoxicity on a panel of cell lines - MDA-MB-231 (IC 50 5.8 nM), SKBR3 (IC 50 5.7 nM) and MCF-7 cells (IC 50 5.8 nM).

In this study, we evaluate the efficacy of the novel proteasome inhibitor BU-32 (NSC D750499) using an in vitro MM model. BU-32 exhibits strong cytotoxicity in a panel of MM cell lines--RPMI8226, MM1S, MM1R, and U266.

potent and selective inhibitor of the chymotrypsin-like activity of the proteasome in vitro. In addition, we show that BU-32 modulates cell-cycle-dependent kinase inhibitors, upregulates p53 and proapoptotic factors Bax and Bid, downregulates NF-κB expression at the protein level, indu.

In this study, we evaluate the efficacy of the novel proteasome inhibitor BU-32 (NSC D750499) using an in vitro MM model. BU-32 exhibits strong cytotoxicity in a panel of multiple myeloma cell lines – RPMI8226, MM1S, MM1R, and U266.

In this study, we evaluate the efficacy of the novel proteasome inhibitor BU-32 (NSC D750499-S) using in vitro and in vivo breast cancer models.

Human peripheral blood lymphocytes were stained with CD19 Brilliant Violet 421™ and CD21 (clone Bu32) PE/Cyanine7 (left) or mouse IgG1, κ PE/Cyanine7 isotype control (right). Compare all formats See PE/Cyanine7 spectral data